{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:08:03Z","timestamp":1790402883985,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clml.2022.12.006","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:26:24Z","timestamp":1670379984000},"page":"e117-e124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Diagnostic Impact of Serum Autotaxin Levels in Patients with Bone Marrow Fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-5052","authenticated-orcid":false,"given":"Hideyuki","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kaiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-919X","authenticated-orcid":false,"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.006_bib0001","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.006_bib0002","series-title":"WHO Classification of Tumours of Haematoopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2022.12.006_bib0003","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0004","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0005","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.006_bib0006","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Fu","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2022.12.006_bib0007","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-013-1776-3","article-title":"The clinical importance of moderate\/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes","volume":"92","author":"Fu","year":"2013","journal-title":"Ann hematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3343\/alm.2022.42.3.299","article-title":"Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update","volume":"42","author":"Jain","year":"2022","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.clml.2022.12.006_bib0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clml.2020.01.003","article-title":"Decoding bone marrow fibrosis in myelodysplastic syndromes","volume":"20","author":"Melody","year":"2020","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.006_bib0010","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/sj.leu.2404917","article-title":"Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia","volume":"21","author":"Buesche","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.006_bib0011","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00277-018-3289-6","article-title":"Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0012","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/cncr.27930","article-title":"Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications","volume":"119","author":"Tadmor","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.006_bib0013","first-page":"12","article-title":"Novel usefulness of krebs von den Lungen 6 (KL-6) with hemoglobin and lactate dehydrogenase for assessing bone marrow fibrosis","author":"Nam","year":"2022","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"10.1016\/j.clml.2022.12.006_bib0014","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2014.11.012","article-title":"PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis","volume":"39","author":"Augello","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.12.006_bib0015","article-title":"Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell reports","volume":"2","author":"Shen","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.clml.2022.12.006_bib0016","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/jth.14433","article-title":"GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis","volume":"17","author":"Lally","year":"2019","journal-title":"J Thrombosis Haemostasis: JTH"},{"key":"10.1016\/j.clml.2022.12.006_bib0017","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","article-title":"Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein","volume":"267","author":"Stracke","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2022.12.006_bib0018","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/stem.2499","article-title":"An lysophosphatidic acid receptors 1 and 3 axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma","volume":"35","author":"Kanehira","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.clml.2022.12.006_bib0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1083\/jcb.200206094","article-title":"Lysophospholipids in the limelight: autotaxin takes center stage","volume":"158","author":"Moolenaar","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clml.2022.12.006_bib0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/bies.20081","article-title":"The ins and outs of lysophosphatidic acid signaling","volume":"26","author":"Moolenaar","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.clml.2022.12.006_bib0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmed.2018.00180","article-title":"Autotaxin in pathophysiology and pulmonary fibrosis","volume":"5","author":"Ninou","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clml.2022.12.006_bib0022","doi-asserted-by":"crossref","first-page":"46705","DOI":"10.1038\/srep46705","article-title":"Association of serum autotaxin levels with liver fibrosis in patients with chronic hepatitis C","volume":"7","author":"Yamazaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.12.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195632","article-title":"Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C","volume":"13","author":"Yamazaki","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.12.006_bib0024","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1038\/s41598-018-26531-0","article-title":"Serum Autotaxin is a useful disease progression marker in patients with primary biliary cholangitis","volume":"8","author":"Joshita","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.12.006_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2141.2008.07325.x","article-title":"Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma","volume":"143","author":"Masuda","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.12.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100691","article-title":"A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management","volume":"45","author":"Garmezy","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2022.12.006_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000067268","article-title":"Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis","volume":"109","author":"Rameshwar","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2022.12.006_bib0029","first-page":"F359","article-title":"Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways to additively increase profibrotic cytokine secretion","volume":"320","author":"Geng","year":"2021","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clml.2022.12.006_bib0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cellsig.2010.10.019","article-title":"Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type \u03b2 receptors and the JNK pathway","volume":"23","author":"Cabello-Verrugio","year":"2011","journal-title":"Cellular signalling"},{"key":"10.1016\/j.clml.2022.12.006_bib0031","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pupt.2018.08.003","article-title":"Pharmacologic targeting of the ATX\/LPA axis attenuates bleomycin-induced pulmonary fibrosis","volume":"52","author":"Ninou","year":"2018","journal-title":"Pulmonary Pharmacol Therap"},{"key":"10.1016\/j.clml.2022.12.006_bib0032","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12079-021-00610-w","article-title":"The linkage between inflammation and fibrosis in muscular dystrophies: the axis autotaxin-lysophosphatidic acid as a new therapeutic target?","volume":"15","author":"Gallardo","year":"2021","journal-title":"J Cell Communication And Signal"},{"key":"10.1016\/j.clml.2022.12.006_bib0033","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ecco-jcc\/jjac017","article-title":"Mesenteric adipocyte contributes to intestinal fibrosis in Crohn...s disease through theATX-LPA axis","volume":"16","author":"Huang","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clml.2022.12.006_bib0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bcp.2019.03.035","article-title":"Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases","volume":"164","author":"Zhao","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2022.12.006_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1158\/1535-7163.MCT-19-0386","article-title":"Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer","volume":"19","author":"Tang","year":"2020","journal-title":"Molr cancer therap"},{"key":"10.1016\/j.clml.2022.12.006_bib0036","first-page":"11","article-title":"Design and Development of Autotaxin Inhibitors","volume":"14","author":"Jia","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.clml.2022.12.006_bib0037","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/cancers12020374","article-title":"Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae","volume":"12","author":"Benesch","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2022.12.006_bib0038","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Resp med"},{"key":"10.1016\/j.clml.2022.12.006_bib0039","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jcp.54.10.737","article-title":"Bone marrow trephine biopsy","volume":"54","author":"Bain","year":"2001","journal-title":"J Clin Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:57Z","timestamp":1761871317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2152265022017517"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Diagnostic Impact of Serum Autotaxin Levels in Patients with Bone Marrow Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}